- Home
- OMER vs MVF Comparison
OMER vs MVF Comparison
Compare OMER & MVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- MVF
- Stock Information
- Founded
- OMER 1994
- MVF 1988
- Country
- OMER United States
- MVF United States
- Employees
- OMER N/A
- MVF N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- MVF Investment Bankers/Brokers/Service
- Sector
- OMER Health Care
- MVF Finance
- Exchange
- OMER Nasdaq
- MVF Nasdaq
- Market Cap
- OMER 397.1M
- MVF 382.4M
- IPO Year
- OMER 2009
- MVF N/A
- Fundamental
- Price
- OMER $3.21
- MVF $6.58
- Analyst Decision
- OMER Strong Buy
- MVF
- Analyst Count
- OMER 5
- MVF 0
- Target Price
- OMER $18.00
- MVF N/A
- AVG Volume (30 Days)
- OMER 808.8K
- MVF 162.8K
- Earning Date
- OMER 08-06-2025
- MVF 01-01-0001
- Dividend Yield
- OMER N/A
- MVF 4.11%
- EPS Growth
- OMER N/A
- MVF N/A
- EPS
- OMER N/A
- MVF N/A
- Revenue
- OMER N/A
- MVF N/A
- Revenue This Year
- OMER N/A
- MVF N/A
- Revenue Next Year
- OMER $468.75
- MVF N/A
- P/E Ratio
- OMER N/A
- MVF N/A
- Revenue Growth
- OMER N/A
- MVF N/A
- 52 Week Low
- OMER $2.97
- MVF $5.85
- 52 Week High
- OMER $13.60
- MVF $7.19
- Technical
- Relative Strength Index (RSI)
- OMER 34.64
- MVF 37.43
- Support Level
- OMER $2.97
- MVF $6.61
- Resistance Level
- OMER $4.06
- MVF $6.70
- Average True Range (ATR)
- OMER 0.26
- MVF 0.05
- MACD
- OMER 0.10
- MVF -0.00
- Stochastic Oscillator
- OMER 22.02
- MVF 7.78
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.